Sponsor Check › Person
Related person on Form D filings · address states as listed: MA, NJ, MN, OH, CA · listed Mar 24, 2015 → Oct 19, 2026
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:56 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
2 of 49 offerings report sales commissions totalling $8,726,979; 0 report finder's fees; 4 report proceeds to related persons totalling $1,508,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Oct 19, 2026 D File 021-601738 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 23, 2026 D File 021-581637 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 14, 2025 D File 021-560739 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 8, 2025 D File 021-550950 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 19, 2024 D File 021-529812 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 29, 2024 D/A File 021-489534 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 14, 2024 D File 021-505327 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 14, 2024 D File 021-505329 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 10, 2022 D File 021-428629 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 21, 2021 D File 021-417842 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 21, 2021 D File 021-417848 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 21, 2021 D File 021-417860 | $3,087,000 | $0 | $0 | SVB Leerink LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Oct 21, 2021 D File 021-417877 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 20, 2021 D/A File 021-396049 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 6, 2021 D File 021-398517 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 5, 2021 D File 021-391380 | $5,639,979 | $0 | $0 | SVB Leerink LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Jan 21, 2021 D File 021-387002 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 18, 2020 D File 021-369265 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 24, 2020 D File 021-365710 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 27, 2020 D File 021-363863 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 12, 2020 D/A File 021-306741 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 28, 2020 D/A File 021-347004 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 13, 2018 D File 021-319020 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 27, 2017 D/A File 021-296213 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 11, 2017 D File 021-290358 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 25, 2016 D File 021-263801 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 3, 2016 D File 021-258524 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 15, 2015 D/A File 021-197489 | $0 | $0 | $768,000 A portion of the proceeds will be used to pay the salaries of the executive officers in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Mar 24, 2015 D/A File 021-225136 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 4, 2015 D File 021-235161 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 8, 2015 D File 021-231795 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 3, 2013 D File 021-207317 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 25, 2013 D File 021-203529 | $0 | $0 | $400,000 (est.) | None listed on this filing |
| EDGAR ↗ | May 17, 2013 D File 021-196697 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 21, 2013 D/A File 021-188257 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 5, 2012 D File 021-187890 | $0 | $0 | $215,000 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 15, 2012 D File 021-174983 | $0 (est.) | $0 (est.) | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jan 13, 2012 D File 021-171774 | $0 | $0 | $125,000 (est.) | None listed on this filing |
| EDGAR ↗ | Aug 26, 2011 D/A File 021-161755 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Sep 28, 2010 D File 021-148242 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 26, 2010 D File 021-145470 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 9, 2010 D File 021-144654 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 25, 2010 D File 021-144039 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 9, 2010 D File 021-143220 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 28, 2010 D File 021-142724 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 9, 2009 D File 021-101585 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 3, 2009 D File 021-50801 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 23, 2009 D File 021-94056 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 14, 2009 D File 021-102715 | $0 | $0 | $0 (est.) | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Adela, Inc. | Director | Oct 19, 2026 | D | $12,000,000 similar: $2,000,000–$19,999,994 | $12,000,000 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adela, Inc. | Director | Apr 23, 2026 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Affinia Therapeutics Inc. | Director | Oct 14, 2025 | D | $45,000,000 similar: $500,000–$7,000,000 | $13,268,335 | 20 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Adela, Inc. | Director | Jul 8, 2025 | D | $27,000,000 similar: $2,000,000–$19,999,994 | $25,425,442 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Zenflow, Inc. | Director | Nov 19, 2024 | D | $25,203,352 similar: $829,831–$9,999,998 | $19,422,855 | 36 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Adela, Inc. | Director | Jul 29, 2024 | D/A | $49,317,173 similar: $2,000,000–$19,999,994 | $48,540,780 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adela, Inc. | Director | Feb 14, 2024 | D | $3,296,554 similar: $2,000,000–$19,999,994 | $3,296,554 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adela, Inc. | Director | Feb 14, 2024 | D | $1,187,700 similar: $2,000,000–$19,999,994 | $1,187,700 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adela, Inc. | Director | Aug 11, 2023 | D | $29,199,991 similar: $2,000,000–$19,999,994 | $28,031,993 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ShouTi Inc. | Director | Jan 10, 2022 | D | $6,999,917 similar: $2,000,000–$19,999,994 | $6,999,917 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ShouTi Inc. | Director | Oct 21, 2021 | D | $100,000,022 similar: $2,000,000–$19,999,994 | $100,000,022 | 30 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ShouTi Inc. | Director | Oct 21, 2021 | D | $32,000,640 similar: $2,000,000–$19,999,994 | $32,000,640 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Basecamp Bio Inc. | Director | Oct 21, 2021 | D | $14,000,000 similar: $2,000,000–$19,999,994 | $9,000,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ShouTi Inc. | Director | Oct 21, 2021 | D | $25,999,992 similar: $2,000,000–$19,999,994 | $25,999,992 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Zenflow, Inc. | Director | May 20, 2021 | D/A | $24,368,845 similar: $829,831–$9,999,998 | $24,368,845 | 43 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Affinia Therapeutics Inc. | Director | May 6, 2021 | D | $109,999,955 similar: $500,000–$7,000,000 | $109,999,955 | 22 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Zenflow, Inc. | Director | Apr 15, 2021 | D | $23,699,998 similar: $829,831–$9,999,998 | $23,699,998 | 40 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Caribou Biosciences, Inc. | Director | Mar 5, 2021 | D | $114,999,613 similar: $2,000,000–$19,999,994 | $114,999,613 | 36 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Xilio Therapeutics, Inc. | Director | Jan 21, 2021 | D | $50,249,990 similar: $2,000,000–$19,999,994 | $50,249,990 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Jun 18, 2020 | D | $100,083,274 similar: $2,000,000–$19,999,994 | $85,083,280 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Apr 24, 2020 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Affinia Therapeutics Inc. | Director | Mar 27, 2020 | D | $68,522,920 similar: $500,000–$7,000,000 | $38,522,942 | 16 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Tempest Therapeutics, Inc. group: Longwood | Director | Feb 12, 2020 | D/A | $100,186,733 similar: $829,831–$9,999,998 | $83,186,733 | 10 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Jan 28, 2020 | D/A | $15,999,999 similar: $2,000,000–$19,999,994 | $15,999,999 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tempest Therapeutics, Inc. group: Longwood | Director | Feb 27, 2019 | D/A | $70,186,738 similar: $829,831–$9,999,998 | $48,186,738 | 8 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Farapulse, Inc. | Director | Aug 13, 2018 | D | $12,000,000 similar: $2,000,000–$19,999,994 | $11,999,993 | 32 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tempest Therapeutics, Inc. group: Longwood | Director | Mar 1, 2018 | D | $70,186,738 similar: $829,831–$9,999,998 | $25,186,738 | 8 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Zenflow, Inc. | Director | Dec 27, 2017 | D/A | $32,224,519 similar: $829,831–$9,999,998 | $31,494,746 | 86 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Farapulse, Inc. | Director | Jul 11, 2017 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Caribou Biosciences, Inc. | Director | May 25, 2016 | D | $30,070,244 similar: $2,000,000–$19,999,994 | $14,459,306 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Farapulse, Inc. | Director | Mar 3, 2016 | D | $23,999,173 similar: $2,000,000–$19,999,994 | $14,999,173 | 35 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Amphora Medical, Inc. | Director | Jul 15, 2015 | D/A | $12,782,106 similar: $829,831–$9,999,998 | $12,782,106 | 8 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Caribou Biosciences, Inc. | Director | Mar 24, 2015 | D/A | $11,549,904 similar: $2,000,000–$19,999,994 | $11,549,904 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Mar 4, 2015 | D | $15,000,000 similar: $1,100,015–$10,001,163 | $15,000,000 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Jan 8, 2015 | D | $16,800,000 similar: $1,100,015–$10,001,163 | $16,273,385 | 10 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Dec 3, 2013 | D | $14,999,993 similar: $1,100,015–$10,001,163 | $14,999,993 | 8 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | BIOCONNECT SYSTEMS INC | Director | Sep 25, 2013 | D | $12,500,000 similar: $2,000,000–$19,999,994 | $9,069,922 | 7 similar: 2–16 | $25,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Amphora Medical, Inc. | Director | Jun 5, 2013 | D | $1,250,000 similar: $829,831–$9,999,998 | $600,000 | 4 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | May 17, 2013 | D | $17,432,178 similar: $1,100,015–$10,001,163 | $14,999,998 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Feb 21, 2013 | D/A | $12,153,073 similar: $1,100,015–$10,001,163 | $10,872,354 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Dec 12, 2012 | D | $6,660,099 similar: $1,100,015–$10,001,163 | $5,872,355 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | BIOCONNECT SYSTEMS INC | Director | Dec 5, 2012 | D | $1,600,000 similar: $2,000,000–$19,999,994 | $1,485,794 | 6 similar: 2–16 | $4,504 similar: $10,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Mar 15, 2012 | D | $26,305,075 similar: $1,100,015–$10,001,163 | $26,305,075 | 18 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | BIOCONNECT SYSTEMS INC | Director | Jan 13, 2012 | D | $938,392 similar: $2,000,000–$19,999,994 | $469,196 | 6 similar: 2–16 | $1,407 similar: $10,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Aug 26, 2011 | D/A | $10,350,000 similar: $1,100,015–$10,001,163 | $10,336,599 | 15 similar: 2–14 | $1,280 similar: $5,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Jun 23, 2011 | D | $10,223,950 similar: $1,100,015–$10,001,163 | $10,000,000 | 8 similar: 2–14 | $1,280 similar: $5,000–$50,000 |
| EDGAR ↗ | TRANSAVE INC | Director | Sep 28, 2010 | D | $6,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 0 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VIEWRAY INC group: Viewray | Director | Jul 26, 2010 | D | $19,998,591 similar: $1,100,015–$10,001,163 | $19,998,591 | 8 similar: 2–14 | $23,000 similar: $5,000–$50,000 |
| EDGAR ↗ | ACCURI CYTOMETERS INC | Director | Jul 9, 2010 | D | $6,000,000 similar: $829,831–$9,999,998 | $6,000,000 | 27 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | TRANSAVE INC | Director | Jun 25, 2010 | D | $5,855,619 similar: $2,000,000–$19,999,994 | $5,499,999 | 0 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ACORN CARDIOVASCULAR INC | Director | Jun 9, 2010 | D | $500,000 similar: $1,100,015–$10,001,163 | $478,476 | 12 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | TETRAPHASE PHARMACEUTICALS INC group: Tetraphase | Director | May 28, 2010 | D | $45,000,000 similar: $1,694,259–$16,000,000 | $44,750,000 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Ikano Therapeutics Inc. | Director | Dec 9, 2009 | D | Indefinite similar: $1,694,259–$16,000,000 | $892,719 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | TRANSAVE INC | Director | Nov 3, 2009 | D | $12,000,000 similar: $2,000,000–$19,999,994 | $5,542,573 | 0 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TETRAPHASE PHARMACEUTICALS INC group: Tetraphase | Director | Sep 23, 2009 | D | $29,627,203 similar: $1,694,259–$16,000,000 | $10,000,000 | 9 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ACCURI CYTOMETERS INC | Director | Jul 14, 2009 | D | $4,000,000 similar: $829,831–$9,999,998 | $3,749,971 | 22 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (5 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Robert Weisskoff. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Robert Weisskoff appears on a new Form D, or when a court case or SEC action is matched to them. See plans →